ArticleJournal of clinical medicine2020

Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab.

Mohamad Cherry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.